Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on SGMO. Wall Street Zen cut Sangamo Therapeutics from a […]
HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on SGMO. Wall Street Zen cut Sangamo Therapeutics from a […]
